NCT01679964View on ClinicalTrials.gov

Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study

PHASE4CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
HIV InfectionAdverse Drug ReactionQuality of Life
Interventions
DRUG

Raltegravir switch

Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)

Trial Locations (7)

108

Taipei City Hospital, Taipei

333

Chang Gung Memorial Hospital at Linkou, Taoyuan District

704

National Cheng Kung University Hospital, Tainan City

807

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

824

E-Da Hospital, Kaohsiung

10048

National Taiwan University Hospital, Taipei

40447

China Medical University Hospital, Taichung

All Listed Sponsors
lead

Lin, Hsi-Hsun, M.D.

INDIV

NCT01679964 - Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study | Biotech Hunter | Biotech Hunter